新诊断不良中等风险前列腺癌患者中PSMA PET/CT的适宜性——基于肿瘤体积的风险分层
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
发表日期:2024 Sep 23
作者:
Marinus J Hagens, Wietske I Luining, Liselotte M S Boevé, Remco J J Knol, Ton A Roeleveld, Sandra Srbljin, Saskia Weltings, Jose C C Koppes, Daniela E Oprea-Lager, André N Vis, Pim J van Leeuwen, Henk G van der Poel
DOI:
10.1038/s41391-024-00899-9
摘要
本研究重新评估了PSMA PET/CT在不良中等风险前列腺癌（PCa）中的诊断价值，并验证了荷兰前列腺癌网络（PCNN）亚分类体系。对接受PSMA PET/CT的男性进行分析，评估转移性疾病的发生率及其与PCNN亚组的相关性。转移性疾病在12.4%的患者中被检测到。较高的PCNN亚组与转移潜能增加相关；低转移潜能病例的比值比显著较低（OR: 0.19, 95% CI 0.06-0.62；p = 0.01）。我们的发现重申了PSMA PET/CT在不良中等风险PCa中的诊断价值，并验证了PCNN亚分类体系，减少了扫描负担达48.1%。
Abstract
This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification.Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups.Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01).Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.